Semi-quantitative Scoring of Skeletal Metastases by I-mIBG Scintigraphy in High-risk Neuroblastoma

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2017 Mar 5

PMID 28258443

Citations 1

Authors

Mark N Gaze

Affiliations

Soon will be listed here.

Citing Articles

How rapid advances in imaging are defining the future of precision radiation oncology.

Beaton L, Bandula S, Gaze M, Sharma R Br J Cancer. 2019; 120(8):779-790.

PMID: 30911090 PMC: 6474267. DOI: 10.1038/s41416-019-0412-y.

References

Liu Y, Lu M, Chang H, Lu C, Lin D, Jou S . Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma. Oncotarget. 2016; 7(14):18774-86. PMC: 4951328. DOI: 10.18632/oncotarget.7933. View

Piccardo A, Puntoni M, Lopci E, Conte M, Foppiani L, Sorrentino S . Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging. 2014; 41(6):1046-56. DOI: 10.1007/s00259-014-2691-0. View

Green M, Lowe J, Kadirvel M, McMahon A, Westwood N, Chua S . Radiosynthesis of no-carrier-added -[I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma. J Radioanal Nucl Chem. 2017; 311(1):727-732. PMC: 5219010. DOI: 10.1007/s10967-016-5073-1. View

Matthay K, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V . Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010; 102(9):1319-26. PMC: 2865749. DOI: 10.1038/sj.bjc.6605621. View

Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F . Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003; 30(5):B45-50. DOI: 10.1007/s00259-003-1138-9. View

Moreno L, Rubie H, Varo A, Cecile Le Deley M, Amoroso L, Chevance A . Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2016; 64(1):25-31. DOI: 10.1002/pbc.26192. View

Basta N, Halliday G, Makin G, Birch J, Feltbower R, Bown N . Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016; 115(9):1048-1057. PMC: 5117794. DOI: 10.1038/bjc.2016.302. View

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

cerny I, Prasek J, Kasparkova H . Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values. Nuklearmedizin. 2016; 55(4):151-7. DOI: 10.3413/Nukmed-0743-15-05. View

10.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

11.

Treuner J, FEINE U, Niethammer D, Meinke J, Eibach E, Dopfer R . Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet. 1984; 1(8372):333-4. DOI: 10.1016/s0140-6736(84)90375-1. View

12.

Huang S, Bolch W, Lee C, Van Brocklin H, Pampaloni M, Hawkins R . Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2014; 17(2):284-94. PMC: 4336853. DOI: 10.1007/s11307-014-0783-7. View

13.

Papathanasiou N, Gaze M, Sullivan K, Aldridge M, Waddington W, Almuhaideb A . 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med. 2011; 52(4):519-25. DOI: 10.2967/jnumed.110.083303. View

14.

Lewington V, Lambert B, Poetschger U, Sever Z, Giammarile F, McEwan A . I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel. Eur J Nucl Med Mol Imaging. 2016; 44(2):234-241. PMC: 5214990. DOI: 10.1007/s00259-016-3516-0. View

15.

Messina J, Cheng S, Franc B, Charron M, Shulkin B, To B . Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006; 47(7):865-74. DOI: 10.1002/pbc.20777. View

16.

Bleeker G, Tytgat G, Adam J, Caron H, Kremer L, Hooft L . 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015; (9):CD009263. PMC: 4621955. DOI: 10.1002/14651858.CD009263.pub2. View

17.

Gains J, Bomanji J, Fersht N, Sullivan T, DSouza D, Sullivan K . 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011; 52(7):1041-7. DOI: 10.2967/jnumed.110.085100. View

18.

Gains J, Mandeville H, Cork N, Brock P, Gaze M . Ten challenges in the management of neuroblastoma. Future Oncol. 2012; 8(7):839-58. DOI: 10.2217/fon.12.70. View

19.

Owens C, Li B, Thomas K, Irwin M . Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma. Pediatr Blood Cancer. 2016; 63(10):1786-93. DOI: 10.1002/pbc.26099. View

20.

Reuland P, GEIGER L, Thelen M, Handgretinger R, Haase B, Muller-Schauenburg W . Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J Pediatr Hematol Oncol. 2002; 23(7):437-42. DOI: 10.1097/00043426-200110000-00009. View